Philadelphia, PA – June 23, 2025 — Pinco Biotherapeutics announced its participation in the 2025 Capital Readiness Program, hosted by the University City Science Center. Pinco was one of 10 innovative companies selected for the intensive bootcamp.

The Capital Readiness Program supports high-potential life sciences startups through structured mentorship, investor readiness preparation, and strategic guidance focused on fundraising execution. Participation includes structured workshops, one-on-one advisory sessions, and pitch refinement in preparation for future institutional fundraising.

“Early-stage biotech companies often face a gap between strong science and investor-ready positioning,” said Scott Alpizar, PhD, CEO of Pinco Biotherapeutics. “The Capital Readiness Program helped us sharpen our capital strategy, refine our milestones, and align our development plan with value-inflection points that matter to investors.”

Pinco is currently raising a pre-seed round to advance its in-vitro proof-of-concept studies, plasmid optimization, and early animal validation work.

About Pinco Biotherapeutics

Pinco Biotherapeutics is a preclinical therapeutics company developing non-viral DNA plasmid–based drugs for chronic neuropathic pain. By directly targeting validated molecular drivers of pain, Pinco’s plasmid is designed to deliver durable, non-addictive relief while avoiding the systemic side effects of small molecules and the immunogenicity risks of viral gene therapies.